Virtual Reality in End Stage Kidney Disease
Launched by UNIVERSITY OF PENNSYLVANIA · Apr 3, 2024
Trial Information
Current as of July 28, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring the use of virtual reality (VR) to see if it can help patients with end stage kidney disease feel better during their hemodialysis treatments. Researchers want to compare two types of VR experiences: one where patients interact with others in a social setting and another where they enjoy individual VR experiences alone. The goal is to find out if these different VR options can reduce symptoms and improve the overall experience for patients during their dialysis sessions.
To participate in this trial, you need to be diagnosed with end stage kidney disease and currently receiving hemodialysis three times a week for at least one month. Unfortunately, if you are currently very ill, experiencing nausea, or have epilepsy, you won't be eligible to join. If you are selected, you will wear VR glasses for about 30 to 45 minutes during your dialysis treatments for four weeks. This study aims to make the time spent on dialysis more enjoyable and potentially improve your symptoms.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • Diagnosis of end stage kidney disease with hemodialysis 3 times per week for at least 1 month
- • Exclusion Criteria
- • Acutely ill
- • Active nausea
- • Epilepsy
About University Of Pennsylvania
The University of Pennsylvania, a prestigious Ivy League institution located in Philadelphia, is renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and cutting-edge facilities to conduct innovative studies across various therapeutic areas. With a focus on translating scientific discoveries into clinical applications, the University of Pennsylvania fosters collaborations among leading researchers, clinicians, and industry partners, ensuring rigorous trial design and adherence to ethical standards. Through its dedication to excellence in research and education, the university plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Lea Ann Matura, PhD
Principal Investigator
University of Pennsylvania
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported